

Helpful Downloads



Sleep Review Article



History and Future PAP Therapy:

Reevaluating the Role of IPAP
in Therapy for OSA

William H. Noah, MD

Founder & Senior Medical Director
Sleep Centers of Middle Tennessee
Chairperson

Middle Tennessee State University Sleep Research Consortium
CEO
SleepRes



Current Volume:

1,000 Office Visits, Sleep Studies, and New PAP Setups per Week



January 2021:

90% increased CPAP usage during year 1

(312 vs 164 min, p-value < 0.00001, n=3884 patients)

JCSM | Journal of
Clinical Sleep Medicine

SCIENTIFIC INVESTIGATIONS

Positive airway pressure therapy supplied by an integrated sleep practice associated with greater adherence among pre-Medicare-aged patients with sleep-disordered breathing

James M. Andry Jr, MD¹; Gabriel Toban, MS²; Cynthia Chafin, MD²; William Noah, MD³

¹Vanderbilt University Medical Center, Nashville, Tennessee; ²MTSU Center for Health and Human Services Sleep Research Consortium, Middle Tennessee State University, Murfreesboro, Tennessee; ³Sleep Centers of Middle Tennessee, MTSU Center for Health and Human Services Sleep Research Consortium, Middle Tennessee State University, Murfreesboro, Tennessee

History Of PAP


- In 1878 Oertel used inspirations of compressed air to treat severe asthma
- In 1887 George Fell used a foot-operated bellows to ventilate opioid overdoses until they recovered
- Alvan Barach et al used PAP to treat pulmonary edema in 1930's
- Used frequently to treat ARDS in the 1970's
- Then in the 1980's to treat OSA

Sullivan et al, *Lancet* April 18, 1981: "Reversal of Obstructive Apnoea by Continuous Positive Airway Pressure through the Nares"



Early CPAPs Had Decreased Inspiratory and Increased Expiratory Pressures

1986, Kingman Strohl and Susan Redline



Sanders & Kern introduce Bilevel PAP in 1990

Obstructive Sleep Apnea Treated by Independently Adjusted Inspiratory and Expiratory Positive Airway Pressures via Nasal Mask*

Physiologic and Clinical Implications

Mark H. Sanders, M.D., F.C.C.P.;† and Nancy Kern, C.R.T.T., R.P.S.G.T

Treatment of obstructive sleep apnea with nasal continuous positive airway pressure mandates simultaneous increases of both inspiratory and expiratory positive airway pressures to eliminate apneas as well as nonapneic oxyhemoglobin desaturation events. We hypothesized that the forces acting to collapse the upper airway during inspiration and expiration are of different magnitudes and that obstructive sleep-disordered breathing events (including apneas, hypopneas and nonapneic desaturation events) could be eliminated at lower levels of EPAP than IPAP. To test these hypotheses, a device was built that allows the independent adjustment of EPAP and IPAP (nasal BiPAP). Our data support the hypotheses that expiratory phase events are important in the pathogenesis of OSA and that there are differences in the magnitudes of the forces destabilizing the upper airway during inspiration and expiration. Finally,

applying these concepts, we have shown that by using a device that permits independent adjustment of EPAP and IPAP, obstructive sleep-disordered breathing can be eliminated at lower levels of expiratory airway pressure compared with conventional nasal CPAP therapy. This may reduce the adverse effects associated with nasal CPAP therapy and improve long-term therapeutic compliance.

(*Chest* 1990; 98:317-24)

OSA=obstructive sleep apnea; CPAP=continuous positive airway pressure; IPAP=inspiratory positive airway pressure; EPAP=expiratory positive airway pressure; PSG=polysonnography; AI=apnea index; DEF=desaturation event frequency; OA=occlusive apnea; CA=central apnea; MA=mixed apnea; OH=obstructive hypopnea; CH=central hypopnea; HI=hypopnea index

Results of Sanders and Kern (1990)

Belief that EPAP treats Apneas and IPAP treats hypopneas

“Crack the airway open with EPAP then blow it open with IPAP”

Belief that inspiratory events (hypopneas/snoring) require higher inspiratory pressure

Thus increase IPAP for hypopneas during titration and their initial bilevel titration protocol is still the basis of the AASM titration guidelines (2008) recommended today

From 1995, bilevel PAP has not shown improved adherence in uncomplicated OSA

Despite little clinical evidence for uncomplicated patients, bilevel PAP has generated financial benefits for suppliers and manufacturers

Philips Introduces CFLEX in 2003



Expiratory Pressure Reduction Algorithms


- 1) Little evidence of increased adherence particularly in larger RCTs
(Bakker et al 2010, Pepin et al 2009)
- 2) Associated with compromised therapy
(Zhu et al 2016)
- 3) Pressure reductions do not transmit to pharynx, merely to the mask
(Masdeu et al 2012)

Engineers engineer to the face, not the pharynx

Mask Compensation Algorithms (Initially introduced Philips in 2009)



React Health, formerly 3B Medical
Luna G3



Philips Respironics Dreamstation 2

Mask Compensation and Resistance



Large → Medium → Small → Extra-Small



Increasing Resistance →

Mask Resistance Compensation Algorithms

Further increasing IPAP to offset increased resistance in certain masks (ie nasal pillows) increases velocity (jetting) against nasal mucosa

Higher IPAP may lead to increased adverse effects such as aerophagia, leak, mouth opening, and potentially TECSA

Remove the advantage of high resistance interface in decreasing IPAP and increasing EPAP which may reduce the overall device pressure setting

Bottom Line Regarding Mask Type Settings on PAP Devices

Respironics (Philips):

- 1) never studied effects of mask compensation algorithms on PAP acceptance or therapy
- 2) never even tested mask resistance compensation algorithms on volunteers/patients (they thought it was just “engineering”)

Testing would have found:

- 1) 100% of new patients preferred the FFM setting with a nasal pillow interface
- 2) no effect on therapy


It was just the “belief” that maintaining IPAP was priority in therapy

The 3 Major Actions of EPAP on the Pharyngeal Airway:

The First Two apply to all OSA patients

EPAP (particularly EEP):



- 1) **Increases** Cross-Sectional Airway
Reduces inspiratory resistance (effort)
(Darcy-Wiesback equation)
- 2) **Increases** End Expiratory Lung Volume (EELV)
Stabilizes UA (tracheal traction)
- **IPAP** does not increase EELV



Optimal EPAP


vs.

Reduced EPAP




End Expiratory Pressure in Relation to P_{crit}

P_{crit} is a Critical Time, not just a Pressure




End Expiratory Pressure in Relation to P_{crit}

P_{crit} is a Critical Time, not just a Pressure




End Expiratory Pressure in Relation to P_{crit}

P_{crit} is a Critical Time, not just a Pressure




EPAP prevents obstruction or collapse of the pharynx by...

Increasing volume



(b)

Increasing stiffness



End-Expiratory Lung Volume Matters:

Why OA, HGN, UPPP, etc are Inferior Therapy

- Heinzer et al found manipulating lung volumes with an iron lung could:
 - (2006) Reduce the mean AHI in half (>60 to <30) by merely increasing EELV (no PAP)
 - (2005) Change therapeutic PAP level required between 5 cmH₂O and 17 cmH₂O
- Stadler et al (2010) compressed the abdomen with a pneumatic cuff to decrease EELV, and found that the pharynx was easier to collapse in obese males with OSA

The Third Advantage of EPAP (EEP): Decreased Work of Breathing (WOB) in Obese Patients


End-expiratory pressure (EEP)...

... increases EELV (FRC)

...which increases lung/chest wall compliance


...and decreases the increased elastic work of breathing in obese individuals

Components of Lung Volume




Obesity and Lung Volume

(Steier et al 2014)



Progression of Work of Breathing in OSA (Lee et al 2016)



Metabolic Compensation





Why do patients develop chronic hypercapnia (elevated CO₂)?

What determines when someone develops chronic (not acute) respiratory failure?

$$P_{\text{AlveolarO}_2} = P_{\text{InspO}_2} - P_{\text{CO}_2} / R$$

CPAP equal to NIV in OHS

(Masa et al., 2019)



- Masa et al. compared CPAP to NIV in OHS
- All parameters improved significantly with both CPAP and NIV including hospitalizations

Since 1990, many PAP Advances have Focused on IPAP > EPAP or maintaining IPAP

Both Sanders and Kern (1990) and Resta et al found that in the setting of adequate EPAP that IPAP (at levels > EPAP) had some effectiveness with hypopneas

But they did not find (nor has anyone else) that IPAP is superior to EPAP in resolving hypopneas

The widespread dogma of “crack the airway open with EPAP and then blow it open with IPAP” has little evidence to support it

Reducing EPAP below optimal level destabilizes the upper airway (and in that setting higher IPAP can reduce obstructive events)



The concept that IPAP is best to treat hypopneas and EPAP is best to treat apneas is simply not true.

Adverse Effects of IPAP>EPAP

- Increased Inspiratory Resistance and Effort
- Aerophagia
- Unintentional Leak/Mouth Openings
- TECSA

Inspiration Obstruction?

Lung volume greatly expands further stabilizing the airway



Schwab et al 1993

Pharyngeal Viscoelastic Nature Overlooked: Starling Resistor Model is Misleading

Changes in airway diameter (shape or folds) have a time constant to change:

- not represented by balloon (Starling model)
- Likely unique for each airway

End-Expiratory airway shape extends into Inspiration (and vice versa)

Examples:

- 1) Nasal EPAP devices
- 2) HGN stimulators

Lung elasticity recoil pressure is increased in patients with OSA

Abdeyrim et al., 2015, found increased lung elastic recoil pressure in patients with OSA

May explain the increased UA resistance beginning during expiration (Sanders 1983)

Think EPAP and less IPAP

Apneas and hypopneas occur at critical pressures and time are determined by:

- The volume of the pharynx
- The volume of the lungs
- The stiffness of the pharyngeal walls

And the viscoelastic nature and elastic recoil

All of these are determined by EPAP, **NOT** IPAP

Does IPAP Increase Pharyngeal Crosssectional Area or Just Increase Inspiratory Pressure Gradient ?

Reducing IPAP relative to EPAP Needed to be investigated

- After 30 years of IPAP > EPAP, adherence rates remain poor
- There is an optimal EPAP to stabilize each airway


Yet, no commercially available bilevel device can reduce IPAP < EPAP so.....

V-Com™ : Testing the Theory


- Adding non-compensated resistance
- **July 2021:** Design and 3-D Print an inline resistor
 - Resistance to flow: 2.0 cmH₂O at 50 L/min
 - Dropped IPAP, but maintained EPAP
 - Comfort was obvious
- **January 2022:** Redesign resistor for injection molding
 - Resistance to flow lowered: 1.7 cmH₂O at 50 L/min
- **June 2022:** V-Com™ introduced at APSS
 - Now with FDA requirements met, patient use began



Resistance in the PAP Circuit




Inspiration: High Flow Large Pressure Drop



Inspiratory Pressure (IPAP) is Reduced

Exhalation: Low Flow Minimal Pressure Drop




Exhalation Pressure
(EPAP) is Preserved

V-Com™: Does it Effect Therapy?

Parameter	Participants	No V-Com	Std. dev	V-Com	Std. dev	Outcome w/ V-Com**	% Improved by V-Com™
P95%/90% Pressure (cmH₂O)	n=61	11.23	2.82	11.33	3.01	No difference	N/A-
AHI (events/hour)	n=61	2.15	2.37	1.79	1.75	Improved (p-value<0.04)	69% (n=42/61)
Leak (L/min)	n= 43*	12.06	9.50	8.00	7.27	Improved (p-value<0.0001)	88% (n=38/43)
Usage (hours)	n=61	7.27	1.33	7.54	1.43	Improved (p-value<0.03)	64% (n=39/61)

2022 Data from University of Utah



V-Com™ Comfort Data in Patients Initiating PAP

A large DME company in the midwestern US conducted a trial of 47 patients who experienced CPAP during their set-up at their prescription pressure using the same interface both without and then with the V-Com™ in the circuit. Patients were then asked 3 questions regarding their experience.

98% (n=46/47) felt CPAP was *more comfortable* with the V-Com™

98% (n=46/47) believed they were *more likely to use CPAP* with the V-Com™

83% (n=39/47) were *willing to pay \$35 extra out of pocket* to have V-Com™ in their CPAP circuit

(Their manuscript is currently being submitted)

Long-Term CPAP Patients Choose V-Com™

77% of long-term CPAP users prefer PAP with V-Com

- To examine potential adverse effects for V-Com™'s Quality Management System (QMS), 101 patients from a large community-based sleep medicine practice were recruited to examine the V-Com™ in the circuit in regard to effects on auto-titration algorithms (P90/955 pressure), usage time, leak and residual index (AHI).
- Each of the 101 participants were asked to give a written description of their experience with the V-Com™ during the 4 days of use. Of the total, 67% (n=67/101) responded and 77% (n=53/67) elected to continue use of the V-Com™ in their CPAP circuit long term.

Adherence data with V-com

Large DME in Midwest US independently examined 90-day adherence rates in new CPAP patients (n=100) using 4 hours 70% of nights as criteria and found V-Com™ yielded 12% increase in those meeting the criteria

Large DME in Southeast US provided struggling patients with a V-Com™ and found 30-day usage after V-Com™ was twice the 30-days before

Pressure Tolerance during CPAP Titration

V-Com™ improves pressure tolerance during in-lab CPAP titration in **91%** of patients

- During collection of titration PSG data from June 2022 – February 2023 for TECSA and oral leak, sleep technologists were also allowed to add a V-Com™ to the PAP circuit of a patient with pressure intolerance to the point they were about to abort the titration study. During the time period of the study, sleep technologists identified 34 patients with such pressure intolerance. The V-Com™ alleviated the pressure intolerance such that the titration study could continue and be completed in 91% (n=31/34) of those patients.
- Statistics still in process. Manuscript preparation not begun

Eliminating Need for Chinstraps

- V-Com™ reduced the need for chinstraps in 85% (n=53/62) of 400 consecutive patients undergoing titration polysomnogram (PSG)
- The chinstrap was indicated (based on sleep technician assessment) in 16% (n=62/400) of titrations and V-Com™ was introduced first in all 62 cases. The V-Com™ avoided the need for a chinstrap in 85% (n=53/62) of cases, despite therapy pressure being further increased after the V-Com™ in many of these titration studies.
- Manuscript in preparation

Treatment-Emergent Central Sleep Apnea (TECSA)

- \dot{V} -Com™ improved treatment emergent central sleep apnea (TECSA) in **100%** (n=17/17) and resolved 94% (16/17) of patients developing TECSA during 1000 consecutive titration PSGs
- With C-Flex+ **on** during titration study (n=500) there were 14 cases of TECSA (2.8%) and with C-Flex **off** (n=500) 3 cases of TECSA (0.6%)
- Our hypothesis was that TECSA resulted from augmented tidal volumes (V_t) and increased \dot{V}_m from PAP therapy, particularly when IPAP greater than EPAP provides PS. While increased loop gain is likely involved, there must be some increase in \dot{V}_m to reduce $ETCO_2$ below the apneic threshold.

Manuscript ready for submission

IPAP

EPAP



IPAP

EPAP

IPAP

EPAP

The Future of PAP Therapy



Let Patients Choose Comfort

- What constitutes sufficient evidence for use regarding comfort?
- Just like choosing a mask for comfort, let patients choose comfort with V-Com™
- Insist your patients always experience V-Com during PAP set-up and choose for themselves



References

1. Strohl KP, Redline S. (1986). Nasal CPAP therapy, upper airway muscle activation, and obstructive sleep apnea. *Am Rev Respir Dis*, 1986;134(3):555-558. doi: 10.1164/arrd.1986.134.3.555.

2.

Sanders, M. H., & Kern, N. (1990). Obstructive Sleep Apnea Treated by Independently Adjusted Inspiratory and Expiratory Positive Airway Pressures via Nasal Mask. *Chest*, 98(2), 317–324. <https://doi.org/10.1378/chest.98.2.317>

3.

Mansukhani MP, Kolla BP, Olson EJ, Ramar K, Morgenthaler TI. (2014). Bilevel positive airway pressure for obstructive sleep apnea. *Expert Rev of Med Devices*, 11(3): doi: [10.1586/17434440.2014.900435](https://doi.org/10.1586/17434440.2014.900435)

4.

Omobomi O, Quan SF. (2020). BPAP for CPAP failures: For the many or the few. *Respirology*, 25(4):358-359. doi: [10.1111/resp.13687](https://doi.org/10.1111/resp.13687)

5.

Resta, O., Guido, P., Picca, V., Scarpelli, F., & Foschino, M. P. (1999). The role of the expiratory phase in obstructive sleep apnoea. *Respir Med*, 93(3), 190–195. [https://doi.org/10.1016/s0954-6111\(99\)90007-0](https://doi.org/10.1016/s0954-6111(99)90007-0)

6.

Sériès, F., & Marc, I. (1998). Effects of inspiratory and expiratory positive pressure difference on airflow dynamics during sleep. *J Appl Physiol*, 85(5), 1855–1862. <https://doi.org/10.1152/jappl.1998.85.5.1855>

7.

Lévy, P., Pépin, J. L., & Ferretti, G. (1994). Dynamique des structures pharyngées au cours des apnées obstructives (en ventilation spontanée, pression positive continue BiPAP). *Neurophysiologie Clinique/Clinical Neurophysiology*, 24(3), 227–248. [https://doi.org/10.1016/s0987-7053\(05\)80187-x](https://doi.org/10.1016/s0987-7053(05)80187-x)

8.

Gugger, M., & Vock, P. (1992). Effect of reduced expiratory pressure on pharyngeal size during nasal positive airway pressure in patients with sleep apnoea: evaluation by continuous computed tomography. *Thorax*, 47(10), 809-813. <https://doi.org/10.1136/thx.47.10.809>

9.

Hoffstein, V., Zamel, N., & Phillipson, E. A. (1984). Lung Volume Dependence of Pharyngeal Cross-Sectional Area in Patients with Obstructive Sleep Apnea. *Am Rev Respir Dis*, 130(2), 175–178. <https://doi.org/10.1164/arrd.1984.130.2.175>

10.

Burger, C. D., Stanson, A. W., Daniels, B. K., Sheedy, P. F., & Shepard, J. W. (1992). Fast-CT Evaluation of the Effect of Lung Volume on Upper Airway Size and Function in Normal Men. *Am Rev Respir Dis*, 146(2), 335–339. <https://doi.org/10.1164/ajrccm/146.2.335>

11.

Schneider, H., Krishnan, V., Pichard, L. E., Patil, S. P., Smith, P. L., & Schwartz, A. R. (2009). Inspiratory duty cycle responses to flow limitation predict nocturnal hypoxemia. *Eur Respir J*, 33(5), 1068–1076. <https://doi.org/10.1183/09046460.00063008>

12.

Berry, R. B., & Gleason, K. (1997). Respiratory Arousal From Sleep: Mechanisms and Significance. *Sleep*, 20(8), 654–675. <https://doi.org/10.1093/sleep/20.8.654>

References

13. Pejin, Z., Karadeniz, D., Öztürk, L., Gözükirmizi, E., & Kaynak, H. (2003). The role of mean inspiratory effort on daytime sleepiness. *Eur Respir J*, 21(4), 688–694. <https://doi.org/10.1183/09031936.03.00298903>
14. Lee, M.-Y., Lin, C.-C., Shen, S.-Y., Chiu, C.-H., & Liaw, S.-F. (2009). Work of Breathing in Eucapnic and Hypercapnic Sleep Apnea Syndrome. *Respiration*, 77(2), 146–151. doi.org/10.1159/000140491
15. Heinzer, R. C., Stanchina, M. L., Malhotra, A., Fogel, R. B., Patel, S. R., Jordan, A. S., Schory, K., & White, D. P. (2005). Lung Volume and Continuous Positive Airway Pressure Requirements in Obstructive Sleep Apnea. *Am J Respir Crit Care Med*, 172(1), 114–117. <https://doi.org/10.1164/rccm.200404-552oc>
16. Series, F., Cormier, Y., & Desmeules, M. (1990). Influence of passive changes of lung volume on upper airways. *J Appl Physiol*, 68(5), 2159–2164. <https://doi.org/10.1152/jappl.1990.68.5.2159>
17. Schwab, R. J., Geffer, W. B., Hoffman, E. A., Gupta, K. B., & Pack, A. I. (1993). Dynamic Upper Airway Imaging during Awake Respiration in Normal Subjects and Patients with Sleep Disordered Breathing. *Am Rev Respir Dis*, 148(5), 1385–1400. <https://doi.org/10.1164/ajrccm/148.5.1385>
18. Sullivan, Colin E., Berthon-Jones, M., Issa, Faiq G., & Eves, L. (1981). Reversal of Obstructive Sleep Apnoea by Continuous Positive Airway Pressure Applied Through the Nares. *The Lancet*, 317(8225), 862–865. [https://doi.org/10.1016/s0140-6736\(81\)92140-1](https://doi.org/10.1016/s0140-6736(81)92140-1)
19. Remmers, J. E., deGroot, W. J., Sauerland, E. K., & Anch, A. M. (1978). Pathogenesis of upper airway occlusion during sleep. *J Appl Physiol*, 44(6), 931–938. <https://doi.org/10.1152/jappl.1978.44.6.931>
20. Mahadevia, A., Onal, E., & Lopata, M. (1983). Effects of Expiratory Positive Airway Pressure on Sleep-induced Respiratory Abnormalities in Patients with Hypersomnia-Related Sleep Apnea Syndrome. *Am Rev of Respir Dis*, 128(4), 708–711. <https://doi.org/10.1164/arrd.1983.128.4.708>
21. Sanders, M. H., & Moore, S. E. (1983). Inspiratory and Expiratory Partitioning of Airway Resistance during Sleep in Patients with Sleep Apnea 1,2. *Am Rev Respir Dis*, 128(4), 554–558. <https://doi.org/10.1164/arrd.1983.127.5.554>
22. Tamisier, R., Pepin, J. L., Wuyam, B., Deschaux, C., & Levy, P. (2004). Expiratory Changes in Pressure: Flow Ratio During Sleep in Patients with Sleep-disordered Breathing. *Sleep*, 27(2), 240–248. <https://doi.org/10.1093/sleep/27.2.240>
23. Morrell, M. J., Arabi, Y., Zahn, B., & Badr, M. S. (1998). Progressive Retropalatal Narrowing Preceding Obstructive Apnea. *Am J Respir Crit Care Med*, 158(6), 1974–1979. doi.org/10.1164/ajrccm.158.6.9712107
24. Badia, Ferré, B., Montserrat, J., Ballester, E., Hernandez, J., Botet, M., Rodriguez-Boisig, P., & Navajas, D. (1998). Forced oscillation technique for the evaluation of

36.

Gilmartin GS, Daly RW, Thomas RJ. Recognition and management of complex sleep-disordered breathing. (2005). *Curr Opin in Pulm Med*, 11(6):485-493.

doi:10.1097/01.mcp.0b00138306.08665.b0

37.

Shirlaw, T., Hanssen, K., Duce, B., & Hukins, C. (2017). A Randomized Crossover Trial Comparing Autotitrating and Continuous Positive Airway Pressure in Subjects With Symptoms of Aerophagia: Effects on Compliance and Subjective Symptoms. *J of Clin Sleep Med*, 13(07), 881–888. <https://doi.org/10.5664/jcsm.6658>

38.

Shepherd, K., Hillman, D., & Eastwood, P. (2013). Symptoms of Aerophagia Are Common in Patients on Continuous Positive Airway Pressure Therapy and Are Related to Presence of Nighttime Gastroesophageal Reflux. *J of Clin Sleep Med*, 09(01), 13–17. <https://doi.org/10.5664/jcsm.2328>

39.

Lebret, M., Arnol, N., Martinot, J.-B., Lambert, L., Tamisier, R., Pepin, J.-L., & Borel, J.-C. (2018). Determinants of Unintentional Leaks During CPAP Treatment in OSA. *Chest*, 153(4), 834–842. <https://doi.org/10.1016/j.chest.2017.08.017>

40.

Landry, S. A., Joosten, S. A., Eckert, D. J., Jordan, A. S., Sands, S. A., White, D. P., Malhotra, A., Wellman, A., Hamilton, G. S., & Edwards, B. A. (2017). Therapeutic CPAP Predicts Upper Airway Collapsibility in Patients With Obstructive Sleep Apnea. *Sleep*, 40(6). <https://doi.org/10.1093/sleep/zsx056>

41.

Horner, R. L. (1996). Motor Control of the Pharyngeal Musculature and Implications for the Pathogenesis of Obstructive Sleep Apnea. *Sleep*, 19(10), 827–853. <https://doi.org/10.1093/sleep/19.10.827>

42.

Heinzer, R C. (2006). Effect of increased lung volume on sleep disordered breathing in patients with sleep apnoea. *Thorax*, 61(5), 435–439. <https://doi.org/10.1136/thx.2005.052084>

43.

Van de Graaff, W. B. (1988). Thoracic influence on upper airway patency. *J Appl Physiol*, 65(5), 2124–2131. <https://doi.org/10.1152/jappl.1988.65.5.2124>

44.

Squier, S. B., Patil, S. P., Schneider, H., Kirkness, J. P., Smith, P. L., & Schwartz, A. R. (2010). Effect of end-expiratory lung volume on upper airway collapsibility in sleep and women. *J Appl Physiol*, 109(4), 977–985. <https://doi.org/10.1152/jappphysiol.00080.2010>

45.

Heinzer, R C. (2006). Effect of increased lung volume on sleep disordered breathing in patients with sleep apnoea. *Thorax*, 61(5), 435–439. <https://doi.org/10.1136/thx.2005.052084>

46.

Braga, C. W., Chen, Q., Burschtin, O. E., Rapoport, D. M., & Ayappa, I. (2011). Changes in lung volume and upper airway using MRI during application of nasal expiratory airway pressure in patients with sleep-disordered breathing. *J Appl Physiol*, 111(5), 1400–1409. <https://doi.org/10.1152/jappphysiol.00218.2011>

47.

Watson, R. A., & Pride, N. B. (2005). Postural changes in lung volumes and respiratory resistance in subjects with obesity. *J Appl Physiol*, 98(2), 512–517. <https://doi.org/10.1152/jappphysiol.00430.2004>

48.

References

49.

Stadler, D. L., McEvoy, R. D., Bradley, J., Paul, D., & Catcheside, P. G. (2010). Changes in lung volume and diaphragm muscle activity at sleep onset in obese obstructive sleep apnea patients vs. healthy-weight controls. *J Appl Physiol*, 109(4), 1027–1036. <https://doi.org/10.1152/jappphysiol.01397.2009>

50.

Stadler, D. L., McEvoy, R. D., Sprecher, K. E., Thomson, K. J., Ryan, M. K., Thompson, C. C., & Catcheside, P. G. (2009). Abdominal Compression Increases Upper Airway Collapsibility During Sleep in Obese Male Obstructive Sleep Apnea Patients. *Sleep*, 32(12), 1579 - 1587. <https://doi.org/10.1093/sleep/32.12.1579>

51.

Joosten, S. A., Sands, S. A., Edwards, B. A., Hamza, K., Turton, A., Lau, K. K., Crossett, M., Berger, P. J., & Hamilton, G. S. (2015). Evaluation of the role of lung volume, airway size and shape in supine-predominant obstructive sleep apnoea patients. *Respirology*, 20(5), 819–827. <https://doi.org/10.1111/resp.12549>

52.

Kent, D. T., Zealear, D., & Schwartz, A. R. (2021a). Ansa Cervicalis Stimulation. *Chest*, 159(3), 1212–1221. <https://doi.org/10.1016/j.chest.2020.10.010>

53.

Kent, D. T., Zealear, D., & Schwartz, A. R. (2021b). Ansa Cervicalis and Hypoglossal Nerve Stimulation in a Patient With Obstructive Sleep Apnea. *Otolaryngol. Head & Surg*, 165(4), 602–604. <https://doi.org/10.1177/0194599820986578>

54.

Smith, P. L., Wise, R. A., Gold, A. R., Schwartz, A. R., & Permutt, S. (1988). Upper airway pressure-flow relationships in obstructive sleep apnea. *J Appl Physiol*, 64(2), 775–795. <https://doi.org/10.1152/jappphysiol.1988.64.2.789>

55.

Gold, A. R., & Schwartz, A. R. (1996). The Pharyngeal Critical Pressure. *Chest*, 110(4), 1077–1088. <https://doi.org/10.1378/chest.110.4.1077>

56.

Oliven, A., Kaufman, E., Kaynan, R., Oliven, R., Steinfeld, U., Tov, N., Odeh, M., Gaitini, L., Schwartz, A. R., & Kimmel, E. (2010). Mechanical parameters determining pharyngeal collapsibility in patients with sleep apnea. *J Appl Physiol*, 109(4), 1037–1044. <https://doi.org/10.1152/jappphysiol.00019.2010>

57.

Genta, P. R., Edwards, B. A., Sands, S. A., Owens, R. L., Butler, J. P., Loring, S. H., White, D. P., & Wellman, A. (2016b). Tube Law of the Pharyngeal Airway in Sleeping Patients with Obstructive Sleep Apnea. *Sleep*, 39(2), 337–343. <https://doi.org/10.5665/sleep.5440>

58.

Kairaitis, K. (2012). Pharyngeal wall fold influences on the collapsibility of the pharynx. *Medical Hypotheses*, 79(3), 372–376. <https://doi.org/10.1016/j.mehy.2012.05.040>

59.

Sleeper, G., Rashidi, M., Strohl, K. P., Najimi, N., Chen, P.-L., El Ghouli, R., & Chiang, A. A. (2022). Comparison of expiratory pressures generated by four different EPAP devices in a laboratory bench setting. *Sleep Medicine*, 96, 87–92. <https://doi.org/10.1016/j.sleep.2022.05.004>

References

60. Abdeyrim, A., Zhang, Y., Li, N., Zhao, M., Wang, Y., Yao, X., Keyoumu, Y., & Yin, T. (2015). Impact of obstructive sleep apnea on lung volumes and mechanical properties of the respiratory system in overweight and obese individuals. *BMC Pulm Med*, 15(1). <https://doi.org/10.1186/s12890-015-0063-6>
61. Van Ryswyk, E., Anderson, C. S., Antic, N. A., Barbe, F., Bittencourt, L., Freed, R., Heeley, E., Liu, Z., Loffler, K. A., & Lorenzi-Filho, G. (2019). Predictors of long-term adherence to continuous positive airway pressure in patients with obstructive sleep apnea and cardiovascular disease. *Sleep*, 42(10). <https://doi.org/10.1093/sleep/zsz100>
62. Rotenberg, B. W., Murariu, D., & Pang, K. P. (2016). Trends in CPAP adherence over twenty years of data collection: a flattened curve. *J of Otolaryngol - Head & Neck Surg*, 45(1). <https://doi.org/10.1186/10912273-016-0156-0>
63. Weaver, T. E., & Grunstein, R. R. (2008). Adherence to Continuous Positive Airway Pressure Therapy: The Challenge to Effective Treatment. *Proc of the Amer Thor Soc*, 5(2), 173–178. <https://doi.org/10.1513/pats.200708-119MG>
64. Andry, J. M., Toban, G., Chafin, C., & Noah, W. (2021). Positive airway pressure therapy supplied by an integrated sleep practice associated with greater adherence in pre-Medicare-aged patients with sleep-disordered breathing. *J of Clin Sleep Med*, 17(1), 31–36. <https://doi.org/10.5664/jcsm.8786>
65. Haynes, R., McDonald, H., Garg, A., & Montague, P. (2002). Interventions for helping patients to follow prescriptions for medications. *Cochrane Database of Systematic Reviews*, <https://doi.org/10.1002/14651858.CD000011>
66. Sackett, D. L., Haynes, R. B., Gibson, E. S., Taylor, D. W., Roberts, R. S., & Johnson, A. L. (1978). Patient compliance with antihypertensive regimens. *Patient Care*, 12(1), 18–21. [https://doi.org/10.1016/s0738-3991\(78\)80033-0](https://doi.org/10.1016/s0738-3991(78)80033-0)
67. DiMatteo, M. R. (2004). Variations in Patients' Adherence to Medical Recommendations. *Medical Care*, 42(3), 200–209. <https://doi.org/10.1097/01.mlr.0000114908.90000.00>
68. Jouett, N. P., Smith, M. L., Watenpaugh, D. E., Siddiqui, M., Ahmad, M., & Siddiqui, F. (2017). Rapid-eye-movement sleep-predominant central sleep apnea relieved with continuous positive airway pressure: a case report. *Physiol Rep*, 5(9), e13254. <https://doi.org/10.14814/phy2.13254>
69. Budhiraja R et al. Early CPAP use identifies subsequent adherence to CPAP therapy. *Sleep*, 2007;30(3):320-324. <https://doi.org/10.1093/sleep/30.3.320>